Serving To Educate Primary Care Clinicians On Respiratory Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News

Primary Care Respiratory Group is pleased to partner with IPCRG (International Primary Care Respiratory Group) and Consultant360 to offer PCRG members up to date Respiratory news.

Articles from these partners will be posted here as they become available and can also be found on their websites.

 
Articles from our Partners at Consultant 360 June 2018
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 May 2018
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 April 2018
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 March 2018
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 February 2018
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 January 2018
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 December 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 November 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 October 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 September 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 August 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 July 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 June 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 May 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 April 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 March 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 February 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 January 2017
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 December 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

IPCRG Suite of Assessment Tools
IPCRG Suite of Assessment Tools
READ MORE...

Articles from our Partners at Consultant 360 November 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 October 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Articles from our Partners at Consultant 360 September 2016
Articles from our Partners at Consultant 360 September 2016
READ MORE...

Articles from our Partners at Consultant 360 August 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Prescriber's Letter August 2016
You'll hear controversy about the efficacy of the intranasal flu vaccine (FluMist)...due to new CDC evidence. It suggests the intranasal vaccine is now only about 3% effective in kids and teens...compared to about 63% with the injectable.
READ MORE...

Articles from our Partners at Consultant 360 July 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Prescriber's Letter July 2016
You'll see more hepatitis C treated in primary care. Hep C now kills more Americans than any other infectious disease...and about half of hep C patients don't know they're infected. Consider screening for, and managing, hep C...just like you would for heart disease, diabetes, etc.
READ MORE...

Articles from our Partners at Consultant 360 June 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Prescriber's Letter June 2016
Cardiology: You'll see a more individualized approach for how long to use aspirin PLUS another antiplatelet after a coronary stent. We're used to seeing most of these patients get dual antiplatelet therapy (DAPT) for 12 months...often aspirin 81 mg plus clopidogrel.
READ MORE...

Articles from our Partners at Consultant 360 May 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Prescriber's Letter May 2016
OPIOIDS: You'll see stronger efforts to limit opioid use for pain...due to new FDA warnings and CDC prescribing guidelines. Product labeling will contain new, FDA-required boxed warnings for SHORT-acting opioids about abuse, overdose, etc...similar to those already in place for LONG-acting opioids.
READ MORE...

Articles from Consultant 360 April 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Prescriber's Letter April 2016
Gastroenterology: Bad press about dementia and other side effects will raise more questions about appropriate use of PPIs (omeprazole, etc). PPIs are popular because they're so effective and heartburn is common. But up to 70% of PPI use is unnecessary. And PPIs have potential harms. Long-term use is associated with fractures, C. diffdiarrhea, pneumonia, hypomagnesemia, and other risks.
READ MORE...

Articles from Consultant 360 March 2016
Articles from Consultant 360 March 2016
READ MORE...

Prescriber's Letter March 2016
Cardiology: A shift in thinking about the CV benefits of ARBs will lead to more use of ARBs instead of ACE inhibitors. We're used to using ACEIs...since they have more CV outcomes data and SEEMED to have a bigger impact on CV events than ARBs.
READ MORE...

Articles from Consultant 360 February 2016
Respiratory Disease Articles from our Partners at Consultant 360
READ MORE...

Prescriber's Letter February 2016
What are Utibron and Seebri for COPD and where do they fit into therapy? How should Seebri and Utibron be used in COPD?
READ MORE...

Articles from Consultant 360 January 2016
Articles from Consultant 360 January 2016
READ MORE...

Prescriber's Letter January 2016
Prescriber’s Letter addresses the drug therapy issues facing medical professionals. For example: Can an asthma exacerbation be treated with one or two doses of dexamethasone?
READ MORE...

IPCRG Respiratory At@Glance Articles December 2015
IPCRG Respiratory At@Glance Articles December 2015
READ MORE...

IPCRG Respiratory At@Glance Articles October 2015
IPCRG Respiratory At@Glance Articles October 2015
READ MORE...

Articles from Consultant 360 December 2015
Articles from Consultant 360 December 2015
READ MORE...

Prescriber's Letter December 2015
When should Spiriva Respimat (tiotropium) be used for asthma?
READ MORE...

Articles from Consultant 360 November 2015
Articles from Consultant 360 November 2015
READ MORE...

Prescriber's Letter November 2015
You'll hear cautious optimism about cardiovascular benefits with the SGLT2 inhibitor, Jardiance (empagliflozin). Until now, metformin seemed to be the only diabetes med linked to a reduction in cardiovascular events in patients with type 2 diabetes. But new evidence suggests that Jardiance also reduces CV risk. This is a surprise...and has researchers perplexed about the mechanism of CV benefit. But it's likely NOT due to A1C lowering.
READ MORE...

Articles from Consultant 360 October 2015
October 2015 Respiratory Disease Articles from Consultant 360
READ MORE...

Prescriber's Letter October 2015
The new PCSK9 inhibitor, Repatha (rih-PATH-ah, evolocumab), will raise questions about how to help patients stick with a statin. Repatha is similar to Praluent (alirocumab). Both PCSK9 inhibitors are injectable biologics...may lower LDL about 60%...cost about $14,000/yr...and lack long-term outcome and safety data.
READ MORE...

Articles from Consultant 360 September 2015
September 2015 Respiratory Disease Articles from Consultant 360
READ MORE...

Prescriber's Letter September 2015
Entresto (en-TRESS-toh), a new drug for systolic heart failure.
READ MORE...

Articles from Consultant 360 August 2015
Respiratory Disease News from our Partners at Consultant 360
READ MORE...

Prescriber's Letter August 2015
ANTITHROMBOTICS
READ MORE...

Articles from Consultant 360 July 2015
July 2015 Respiratory Disease Articles from Consultant360
READ MORE...

Prescriber's Letter July 2015
PULMONARY EMBOLISM
READ MORE...

PCMG Collaboration with CRS
PCMG Collaboration with CRS
READ MORE...

Articles from Consultant 360 June 2015
June 2015 Respiratory Disease Articles from Consultant360
READ MORE...

Prescriber's Letter June 2015
ProAir RespiClick (PRO-air RES-pee-klik) will be a new dry-powder inhaler version of albuterol
READ MORE...

Prescriber's Letter March 2015
Flonase Allergy Relief will compete with Nasacort Allergy 24HR on OTC shelves.
READ MORE...

Prescriber's Letter January 2015
You’ll see two new anticholinergic inhalers for COPD, Incruse Ellipta (IN-cruise) and Spiriva Respimat. Think of them as different forms of existing agents. Incruse contains the anticholinergic umeclidinium...which is also in the combo inhaler, Anoro Ellipta (umeclidinium/vilanterol).
READ MORE...

Prescriber's Letter December 2014
You’ll see more focus on improving the care of asthma patients while also improving performance on quality measures. Half of all patients with asthma have an exacerbation every year... leading to ED visits, hospital stays, and even deaths. Now there’s more impetus for prescribers and hospitals to reduce admissions...improve use of controller meds...and meet quality measures.
READ MORE...

Prescriber's Letter November 2014
You’ll hear more about “stepping down” inhaled corticosteroids (fluticasone, etc) in patients with severe COPD. Inhaled steroids are usually added to long-acting bronchodilators (tiotropium, salmeterol, etc) in patients with SEVERE COPD. Adding an inhaled steroid may decrease COPD exacerbations...by about one exacerbation per patient every 4 years versus salmeterol alone.
READ MORE...

Prescriber's Letter October 2014
COPD You’ll see Striverdi Respimat (STRIH-ver-dee, olodaterol), a new long-acting beta-agonist maintenance inhaler for COPD. It’s used ONCE daily like Arcapta (indacaterol)...instead of TWICE daily like Foradil (formoterol) or Serevent (salmeterol).
READ MORE...

Prescriber's Letter September 2014
About one in five adults still use tobacco, and your intervention can significantly improve their chances of quitting. Nearly 70% of smokers want to quit...but only about 5% succeed. Explain that meds PLUS counseling works better than either one alone. Help patients choose smoking cessation meds...and use them properly. Keep in mind, the best option is one your patient will use. Ask about what they’ve tried in the past...and how they used it.
READ MORE...

Prescriber's Letter August 2014
You’ll see more focus on using continuous positive airway pressure (CPAP) for obstructive sleep apnea...due to possible CV benefits.
READ MORE...

Prescriber's Letter July 2014
Patients will ask how they can avoid getting Middle East Respiratory Syndrome (MERS).
READ MORE...

Prescriber's Letter June 2014
You'll see three new sublingual immunotherapy tablets...Grastek, Oralair, and Ragwitek. Think of them as an alternative to "allergy shots"...to increase tolerance to certain grass or ragweed allergens. Grastek (GRAS-tek) and Oralair (OR-al-air) are for grass allergies...and Ragwitek (RAG-wuh-tek) is for ragweed allergies. Allergy shots may cost less...and make more sense for patients with multiple allergies. But sublingual tabs are more convenient, safer, and almost as effective as injections.
READ MORE...